We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
FULGENT GENETIC (FLGT - Free Report) closed at $87.64 in the latest trading session, marking a +0.52% move from the prior day. This change outpaced the S&P 500's 0.09% loss on the day.
Heading into today, shares of the company had lost 5.58% over the past month, lagging the Medical sector's gain of 0.3% and the S&P 500's gain of 5.45% in that time.
FLGT will be looking to display strength as it nears its next earnings release, which is expected to be May 6, 2021. On that day, FLGT is projected to report earnings of $5.99 per share, which would represent year-over-year growth of 20066.67%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $317.11 million, up 3991.68% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $12.52 per share and revenue of $776.56 million. These totals would mark changes of +37.58% and +84.14%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for FLGT. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. FLGT is holding a Zacks Rank of #4 (Sell) right now.
Digging into valuation, FLGT currently has a Forward P/E ratio of 6.96. This represents a discount compared to its industry's average Forward P/E of 22.02.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 232, putting it in the bottom 9% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
FULGENT GENETIC (FLGT - Free Report) closed at $87.64 in the latest trading session, marking a +0.52% move from the prior day. This change outpaced the S&P 500's 0.09% loss on the day.
Heading into today, shares of the company had lost 5.58% over the past month, lagging the Medical sector's gain of 0.3% and the S&P 500's gain of 5.45% in that time.
FLGT will be looking to display strength as it nears its next earnings release, which is expected to be May 6, 2021. On that day, FLGT is projected to report earnings of $5.99 per share, which would represent year-over-year growth of 20066.67%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $317.11 million, up 3991.68% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $12.52 per share and revenue of $776.56 million. These totals would mark changes of +37.58% and +84.14%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for FLGT. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. FLGT is holding a Zacks Rank of #4 (Sell) right now.
Digging into valuation, FLGT currently has a Forward P/E ratio of 6.96. This represents a discount compared to its industry's average Forward P/E of 22.02.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 232, putting it in the bottom 9% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.